Cargando…

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

AIMS/OBJECTIVES: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and β(3)‐adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drake, Marcus J., MacDiarmid, Scott, Chapple, Christopher R., Esen, Adil, Athanasiou, Stavros, Cambronero Santos, Javier, Mitcheson, David, Herschorn, Sender, Siddiqui, Emad, Huang, Moses, Stoelzel, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485167/ https://www.ncbi.nlm.nih.gov/pubmed/28419650 http://dx.doi.org/10.1111/ijcp.12944

Ejemplares similares

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
por: Mueller, Elizabeth R., et al.
Publicado: (2019)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
por: Nitti, V W, et al.
Publicado: (2013)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years
por: Özcan, Cihat, et al.
Publicado: (2023)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
por: Kim, Seong Cheol, et al.
Publicado: (2021)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study
por: Tang, Qing-lai, et al.
Publicado: (2022)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
por: Hsiao, Sheng-Mou, et al.
Publicado: (2022)

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
por: Griebling, Tomas L., et al.
Publicado: (2020)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

A review of solifenacin in the treatment of urinary incontinence
por: Basra, Ramandeep, et al.
Publicado: (2008)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
por: Özkidik, Mete, et al.
Publicado: (2019)

Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada
por: Matta, Rano, et al.
Publicado: (2019)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice
por: West, Eliza G., et al.
Publicado: (2022)

Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2014)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Risk factors associated with the progression of overactive bladder among patients with type 2 diabetes
por: Zhu, Yiyi, et al.
Publicado: (2019)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder
por: Lee, L. K., et al.
Publicado: (2015)

Impact of depression on overactive bladder
por: Kawahara, Takashi, et al.
Publicado: (2020)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p4qhn96vh51rjkl7039p5qmj9u